Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 19 December 2023 at 10.30 a.m. (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen____________________________________________Person subject to the notification requirementName: Halonen, JarmoPosition: Member of the Board/Deputy memberIssuer: BBS-Bioactive Bone Substitutes OyjLEI: 743700BYSBP0PCR6N767Notification type: INITIAL NOTIFICATIONReference number:...
Nasdaq GlobeNewswire
19/12/2023
Outlook 2023-2024
Press release issued on December 19, 2023 before financial market opening at 8:30am CET Given the strong rebound in revenue observed in the third quarter and continuing into the fourth quarter,a higher-than-expected margin on production costs, and the confirmed postponement of certain expenses, in particular R&D (increase in the ratio of R&D expenses to revenue of only ~+0.5 points compared with 2022),2023 revenue growth at constant exchange rates and scope is now expected...
Nasdaq GlobeNewswire
19/12/2023
Roche navify digital solutions get excellent ratings from healthcare…
Key insights from the First Look report reveal that: Key insights from the First Look report reveal that: About KLAS ResearchKLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team...
PR Newswire
19/12/2023
In-Depth Market Analysis of Rare Genetic Disorders: Familial Chylomicronemia…
DelveInsight has recently released a series of epidemiology-based market reports focusing on rare genetic disorders including Familial Chylomicronemia Syndrome (FCS), Netherton Syndrome, and Acromegaly. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into 7MM [the United States, the EU-4 (Italy…
PR Newswire
18/12/2023
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for…
Dr. Christian Behrenbruch, Managing Director and Telix Group CEO said, "This is a major milestone and achievement for Telix, which paves the way for a commercial availability for patients in the U.S. in 2024, subject to regulatory review and approval." Dr.Christian Behrenbruch, Managing Director and Telix Group CEO said, "This is a major milestone and achievement for Telix, which paves the way for a commercial availability for patients in the U.S. in 2024, subject to regulatory…
PR Newswire
18/12/2023
PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION…
Piramal Pharma Solutions is a global leader in ADC development and manufacturing, with hundreds of payloads developed and more than a thousand ADC batches manufactured. This expansion further enhances the site's capacity by approximately seventy to eighty percent, enabling scale-up of commercial ADC manufacturing batches. The capacity expansion, which has been completed for commercialization within this fiscal year, features two new ADC manufacturing suites specifically designed to complement…
PR Newswire
18/12/2023
Sanofi: Information concerning the total number of voting rights and shares -…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,036,828 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
18/12/2023
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Africa and future pandemic preparednessBioNTech plans to complete all buildings at the Kigali site and start local training of specialized personnel in the facility in 2024, with test mRNA production for process validation to be initiated in 2025Upon successful validation, the Kigali facility will serve as a lighthouse project for...
Nasdaq GlobeNewswire
18/12/2023
Decision concerning the adoption of a sale plan (plan de cession) and the…
Decision concerning the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings scheduled for January 16, 2024Paris, France, December 18, 2023 – 7:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that following today's hearing, the Paris Commercial Court will...
Nasdaq GlobeNewswire
18/12/2023
3D-Printed Metal Parts Market is Forecast to Reach US$ 43.9 Billion in 2028…
Click here for a free sample pdf: https://www.stratviewresearch.com/Request-Sample/3377/3d-printed-metal-parts-market.html#form Click here for a free sample pdf: https://www.stratviewresearch.com/Request-Sample/3377/3d-printed-metal-parts-market.html#form Report Highlights Segment Insights on 3D-Printed Metal Parts Market The global 3D-Printed Metal Parts Market is segmented based on Metal Type, Manufacturing Process Type, End-Use Industry Type, and Region. Based on...
PR Newswire
18/12/2023
EQT Private Equity to acquire Zeus, a global leader in advanced polymer…
Zeus' components enable the delivery of minimally invasive interventional procedures, which drive significantly better health outcomes than traditional open surgeries, including faster patient recovery and reduced pain, at lower cost. Zeus has experienced substantial growth as a leading innovator in polymer-based solutions. As populations age and chronic conditions become more prevalent, increasing demand for precision, high-performance catheters to support therapeutic areas including structural…
PR Newswire
18/12/2023
Casino Group Communication
Casino Group announces exclusive discussions with Auchan Retail and Groupement Les Mousquetaires for the sale of Casino hypermarkets and supermarkets Paris, 18 December 2023Casino Group, on the one hand, and Groupement Les Mousquetaires and Auchan Retail, on the other hand, announce that they have entered into exclusive negotiations today with a view to the proposed sale by Casino Group of substantially all of Casino Group's hypermarkets and supermarkets 1to Groupement Les...
Nasdaq GlobeNewswire
18/12/2023
Tissue Engineering Market worth $8.9 billion - Exclusive Report by…
Browse in-depth TOC on "Tissue Engineering Market"364 - Tables49 - Figures358 - Pages Browse in-depth TOC on "Tissue Engineering Market" 364 - Tables 49 - Figures 358 - Pages Tissue Engineering Market Scope: The scaffolds product type segment accounted for the largest share of the product type segment in the tissue engineering market in 2022. Based on product type, the tissue engineering market has been segmented into scaffolds, tissue grafts, and other products...
PR Newswire
18/12/2023
EQT Private Equity to acquire Zeus, a global leader in advanced polymer…
Zeus' components enable the delivery of minimally invasive interventional procedures, which drive significantly better health outcomes than traditional open surgeries, including faster patient recovery and reduced pain, at lower cost. Zeus has experienced substantial growth as a leading innovator in polymer-based solutions. As populations age and chronic conditions become more prevalent, increasing demand for precision, high-performance catheters to support therapeutic areas including structural…
PR Newswire
18/12/2023
Affidea Group implements a state-of-the-art Digital Quality Management System
The key focus areas of the new Quality Management System will include: The key focus areas of the new Quality Management System will include: Affidea Romania will spearhead the adoption of the new Quality Management System, followed by Affidea Italy,Switzerland, and the Corporate HQ. This phased rollout will serve as a learning experience for subsequent implementations in other Affidea countries. DrCharles Niehaus, Executive Director for Affidea Group, said: In the ever-evolving...
PR Newswire
18/12/2023
BBS-Bioactive Bone Substitutes Plc's rights issue raised gross proceeds of EUR…
BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider information, 18 December 2023 at 5:15 p.m.BBS-Bioactive Bone Substitutes Plc's rights issue raised gross proceeds of EUR 1.87 million NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.The rights issue resolved by BBS-Bioactive Bone...
Nasdaq GlobeNewswire
18/12/2023
Advanced Wound Care Management Market Size & Share to Surpass USD 18.2 billion…
The shift towards value-based care models incentivizes healthcare providers to focus on patient outcomes rather than the volume of services. This paradigm encourages the adoption of advanced wound care solutions that promote quicker healing, reducing hospital readmissions and overall treatment costs. The shift towards value-based care models incentivizes healthcare providers to focus on patient outcomes rather than the volume of services. This paradigm encourages the adoption of advanced…
PR Newswire
18/12/2023
Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance…
Matt Niloff, Chief Commercial Officer of Andelyn, said, "Working collaboratively with Ultragenyx and leveraging our 20 years of AAV experience, we have successfully transferred the UX111 GMP process to our commercial manufacturing facility in Columbus, Ohio. Andelyn is honored to continue its close partnership to advance the UX111 Program to bring treatment to MPS IIIA patients sooner." Matt Niloff, Chief Commercial Officer of Andelyn, said, "Working collaboratively with…
PR Newswire
18/12/2023
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 18 December 2023– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under...
Nasdaq GlobeNewswire
18/12/2023
ACG joins coveted list of WEF's Global Lighthouse Network
The certification comes after robust audit of 25+ use cases for the facility, that have not only led to manufacturing of superior quality products but also, transformed operations creating new benchmarks for timely production. ACG's Pithampur factory exemplifies accelerated deployment of GenAI, addressing the evolving skill sets of employees in manufacturing through a remarkable Standard Operating Procedure (SOP) and policy interfacing with Gen AI. The certification comes after robust audit…
PR Newswire
18/12/2023
Muckle Wells Syndrome Market to Reach US$ 335.9 Million by 2030, Rising at a…
Secondly, the rise in research and development activities for the development of novel therapeutics and treatment options is also expected to drive the market. The growing number of clinical trials and investments in research activities have led to the development of targeted therapies for Muckle Wells Syndrome, providing patients with effective and personalized treatment options. Secondly, the rise in research and development activities for the development of novel therapeutics and treatment...
PR Newswire
18/12/2023
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120…
All Viatris' biosimilars brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart) are now part of Biocon Biologics' commercial franchise in Advanced Markets and 80+ Emerging Markets. Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia. All Viatris' biosimilars…
PR Newswire
18/12/2023
SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining…
SyntheticMR's new 3D release is a next-generation imaging solution that is poised to revolutionize the field of medical imaging by introducing a myriad of innovative applications within SyMRI's post-processing solution. This advanced SyMRI sequence introduces 3D resolution to quantitative values and tissue segmentations, ensuring the same level of precision in quantification as achieved with SyMRI's 2D imaging. SyntheticMR's new 3D release is a next-generation imaging solution that is poised…
PR Newswire
18/12/2023
Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
Henrijette Richter, Managing Partner of Sofinnova Partners and Vice Chair of the Board of Directors of Asceneuron, commented: "Abbas has fantastic experience and a proven track record in the pharma industry which will be invaluable as we take Asceneuron into its next stage of growth and accelerate development of these potentially transformative therapies. On behalf of the whole board and company, I would like to thank Peter Van Vlasselaer for his expertise and guidance over the past 5…
PR Newswire
18/12/2023
Altri Comunicati
